Tcr2 Therapeutics Inc’s (TCRR) Quiet Period To Expire Tomorrow

Tcr2 Therapeutics’ (NASDAQ:TCRR) quiet period will expire on Tuesday, March 26th. Tcr2 Therapeutics had issued 5,000,000 shares in its initial public offering on February 14th. The total size of the offering was $75,000,000 based on an initial share price of $15.00. During Tcr2 Therapeutics’ quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

A number of equities research analysts have recently issued reports on the company. BMO Capital Markets assumed coverage on Tcr2 Therapeutics in a research note on Monday, March 11th. They set an “outperform” rating and a $37.00 price objective on the stock. Wedbush assumed coverage on Tcr2 Therapeutics in a research note on Monday, March 11th. They set an “outperform” rating and a $28.00 price objective on the stock. They noted that the move was a valuation call. Leerink Swann assumed coverage on Tcr2 Therapeutics in a research note on Monday, March 11th. They set an “outperform” rating on the stock. Jefferies Financial Group assumed coverage on Tcr2 Therapeutics in a research note on Monday, March 11th. They set a “buy” rating and a $31.00 price objective on the stock. Finally, Svb Leerink assumed coverage on Tcr2 Therapeutics in a research note on Monday, March 11th. They set an “outperform” rating and a $27.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, Tcr2 Therapeutics presently has an average rating of “Buy” and a consensus target price of $30.75.

Shares of Tcr2 Therapeutics stock opened at $17.53 on Monday. Tcr2 Therapeutics has a 12-month low of $14.80 and a 12-month high of $25.47.

In other Tcr2 Therapeutics news, Director Morana Jovan-Embiricos purchased 666,667 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $10,000,005.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Upnorth Investment Ltd purchased 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 19th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $3,000,000.00. The disclosure for this purchase can be found here.

WARNING: This piece was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2019/03/25/tcr2-therapeutics-incs-tcrr-quiet-period-to-expire-tomorrow.html.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Recommended Story: The risks of owning bonds

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.